Skip to main content
Premium Trial:

Request an Annual Quote

Plan No Longer

The UK's National Health Service is backing off from its plan to offer healthy people genomic analysis for a fee, the Guardian reports.

In January, NHS outlined its 10-year plan to expand genetic testing to all children with cancer or a rare genetic disorder, as well as for individuals with high cholesterol. Health Secretary Matthew Hancock said later that month that healthy individuals could also pay to have their genomes analyzed if they also consented to taking part in research, calling them "genomic volunteers." Critics dashed the plan as the utility of sequencing healthy people is unclear and as they thought it set up an inequitable, two-tiered system at NHS where those who could pay would receive more benefits than those who could not.

The Guardian says, buried in a report issued Monday, the "genomic volunteer" plan has been eliminated and replaced by one to instead recruit 5 million healthy volunteers who will have their genomes analyzed without charge. This cohort, it adds, is to also to strive to include individuals from underrepresented groups.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.